blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1589009

EP1589009 - VITAMIN D3 LACTONE DERIVATIVE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.08.2015
Database last updated on 09.07.2024
Most recent event   Tooltip13.10.2017Lapse of the patent in a contracting state
New state(s): BG, HU, TR		published on 15.11.2017  [2017/46]
Applicant(s)For all designated states
Teijin Pharma Limited
1-1, Uchisaiwaicho 2-chome, Chiyoda-ku
Tokyo 100-0011 / JP
[2014/41]
Former [2005/43]For all designated states
Teijin Pharma Limited
1-1, Uchisaiwaicho 2-chome, Chiyoda-ku
Tokyo 100-0011 / JP
Inventor(s)01 / TAKENOUCHI, Kazuya
c/o Teijin Pharma Ltd
Tokyo Research Center
3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
02 / ANZAL, Miyuki
c/o Teijin Pharma Ltd
Tokyo Research Center
3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
03 / SAITO, Hiroshi
c/o Teijin Pharma Ltd
Tokyo Research Center
3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
04 / OKADA, Kazuhisa
c/o Teijin Pharma Ltd
Tokyo Research Center
3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
05 / ISHIZUKA, Seiichi
c/o Teijin Pharma Ltd
Tokyo Research Center
3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
06 / MIURA, Daishiro
c/o Teijin Pharma Ltd
Tokyo Research Center
3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
07 / TAKAYAMA, Hiroaki
6-12, Hatagaya 2-chome
Shibuya-ku
Tokyo 1510072 / JP
08 / KITTAKA, Atsushi
1091-1, Suwarashi, Sagamikomachi
Tsukui-gun Kanagawa 1910106 / JP
09 / SAITO, Nozomi
1091-1, Suwarashi, Sagamikomachi
Ts ukui-gun Kanagawa 1910106 / JP
10 / FUJISHIMA, Toshie
c/o Tokushima Bunri University
Pharmac. Science at Kagawa Campus
1314-1, Shido
Sanuki-city, Kagawa 769-2193 / JP
 [2014/27]
Former [2006/05]01 / TAKENOUCHI, Kazuya, c/o Teijin Pharma Ltd, Tokyo
Research Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
02 / ANZAL, Miyuki, c/o Teijin Pharma Ltd, Tokyo
Researrch Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
03 / SAITO, Hiroshi, c/o Teijin Pharma Ltd, Tokyo
Research Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
04 / OKADA, Kazuhisa, c/o Teijin Pharma Ltd, Tokyo
Research Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
05 / ISHIZUKA, Seiichi, c/o Teijin Pharma Ltd, Tokyo
Research Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
06 / MIURA, Daishiro, c/o Teijin Pharma Ltd, Tokyo
Research Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
07 / TAKAYAMA, Hiroaki
6-12, Hatagaya 2-chome Shibuya-ku Tokyo
1510072 / JP
08 / KITTAKA, Atsushi
1091-1, Suwarashi, Sagamikomachi
Tsukui-gun Kanagawa 1910106 / JP
09 / SAITO, Nozomi
1091-1, Suwarashi, Sagamikomachi
Ts ukui-gun Kanagawa 1910106 / JP
10 / FUJISHIMA, Toshie c/o Tokushima Bunri University
Pharmac. Science at Kagawa Campus 1314-1,Shido
Sanuki-city, Kagawa 769-2193 / JP
Former [2005/43]01 / TAKENOUCHI, Kazuya, c/o Teijin Pharma Ltd, Tokyo
Research Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
02 / ANZAL, Miyuki, c/o Teijin Pharma Ltd, Tokyo
Researrch Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
03 / SAITO, Hiroshi, c/o Teijin Pharma Ltd, Tokyo
Research Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
04 / OKADA, Kazuhisa, c/o Teijin Pharma Ltd, Tokyo
Research Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
05 / ISHIZUKA, Seiichi, c/o Teijin Pharma Ltd, Tokyo
Research Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
06 / MIURA, Daishiro, c/o Teijin Pharma Ltd, Tokyo
Research Center 3-2, Asahigaoka 4-chome
Hino-shi, Tokyo 1910065 / JP
07 / TAKAYAMA, Hiroaki
6-12, Hatagaya 2-chome Shibuya-ku Tokyo
1510072 / JP
08 / KITTAKA, Atsushi
1091-1, Suwarashi, Sagamikomachi
Tsukui-gun Kanagawa 1910106 / JP
09 / SAITO, Nozomi
1091-1, Suwarashi, Sagamikomachi
Ts ukui-gun Kanagawa 1910106 / JP
10 / FUJISHIMA, Toshie
1091-1, Suwarashi, Sagamikomachi
Tsukui-gun Kanagawa 1910106 / JP
Representative(s)Hallybone, Huw George, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2014/41]
Former [2005/43]Hallybone, Huw George, et al
Carpmaels and Ransford, 43 Bloomsbury Square
London WC1A 2RA / GB
Application number, filing date04706334.229.01.2004
[2005/43]
WO2004JP00815
Priority number, dateJP2003002165030.01.2003         Original published format: JP 2003021650
JP2003033965830.09.2003         Original published format: JP 2003339658
[2005/43]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2004067525
Date:12.08.2004
Language:EN
[2004/33]
Type: A1 Application with search report 
No.:EP1589009
Date:26.10.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 12.08.2004 takes the place of the publication of the European patent application.
[2005/43]
Type: B1 Patent specification 
No.:EP1589009
Date:08.10.2014
Language:EN
[2014/41]
Search report(s)International search report - published on:JP12.08.2004
(Supplementary) European search report - dispatched on:EP09.04.2008
ClassificationIPC:C07D307/58, A61K31/593, A61P3/10, A61P3/14, A61P5/18, A61P9/12, A61P11/00, A61P17/00, A61P17/06, A61P17/10, A61P17/14
[2005/43]
CPC:
C07D307/58 (EP,KR,US); A61K31/593 (EP,KR,US); A61P11/00 (EP);
A61P17/00 (EP); A61P17/06 (EP); A61P17/10 (EP);
A61P17/14 (EP); A61P19/00 (EP); A61P19/08 (EP);
A61P3/02 (EP); A61P3/10 (EP); A61P3/14 (EP);
A61P5/18 (EP); A61P9/12 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/43]
TitleGerman:VITAMIN-D3-LACTON-DERIVAT[2005/43]
English:VITAMIN D3 LACTONE DERIVATIVE[2005/43]
French:DERIVE DE LACTONE DE LA VITAMINE D3[2005/43]
Entry into regional phase21.07.2005Translation filed 
21.07.2005National basic fee paid 
21.07.2005Search fee paid 
21.07.2005Designation fee(s) paid 
21.07.2005Examination fee paid 
Examination procedure21.07.2005Examination requested  [2005/43]
14.05.2009Despatch of a communication from the examining division (Time limit: M06)
24.11.2009Reply to a communication from the examining division
16.04.2010Despatch of a communication from the examining division (Time limit: M04)
08.07.2010Reply to a communication from the examining division
31.08.2012Despatch of a communication from the examining division (Time limit: M04)
21.12.2012Reply to a communication from the examining division
04.06.2014Communication of intention to grant the patent
27.08.2014Fee for grant paid
27.08.2014Fee for publishing/printing paid
27.08.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  14.05.2009
Opposition(s)09.07.2015No opposition filed within time limit [2015/38]
Fees paidRenewal fee
21.07.2005Renewal fee patent year 03
12.01.2007Renewal fee patent year 04
14.01.2008Renewal fee patent year 05
14.01.2009Renewal fee patent year 06
13.01.2010Renewal fee patent year 07
14.01.2011Renewal fee patent year 08
11.01.2012Renewal fee patent year 09
10.01.2013Renewal fee patent year 10
21.01.2014Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.01.2004
AT08.10.2014
BG08.10.2014
CY08.10.2014
CZ08.10.2014
DK08.10.2014
EE08.10.2014
ES08.10.2014
FI08.10.2014
IT08.10.2014
MC08.10.2014
NL08.10.2014
RO08.10.2014
SE08.10.2014
SI08.10.2014
SK08.10.2014
TR08.10.2014
GR09.01.2015
IE29.01.2015
LU29.01.2015
BE31.01.2015
CH31.01.2015
LI31.01.2015
PT09.02.2015
[2017/39]
Former [2016/12]AT08.10.2014
CY08.10.2014
CZ08.10.2014
DK08.10.2014
EE08.10.2014
ES08.10.2014
FI08.10.2014
IT08.10.2014
MC08.10.2014
NL08.10.2014
RO08.10.2014
SE08.10.2014
SI08.10.2014
SK08.10.2014
GR09.01.2015
IE29.01.2015
LU29.01.2015
BE31.01.2015
CH31.01.2015
LI31.01.2015
PT09.02.2015
Former [2016/07]AT08.10.2014
CY08.10.2014
CZ08.10.2014
DK08.10.2014
EE08.10.2014
ES08.10.2014
FI08.10.2014
IT08.10.2014
MC08.10.2014
NL08.10.2014
RO08.10.2014
SE08.10.2014
SK08.10.2014
GR09.01.2015
IE29.01.2015
LU29.01.2015
BE31.01.2015
CH31.01.2015
LI31.01.2015
PT09.02.2015
Former [2015/47]AT08.10.2014
CY08.10.2014
CZ08.10.2014
DK08.10.2014
EE08.10.2014
ES08.10.2014
FI08.10.2014
IT08.10.2014
MC08.10.2014
NL08.10.2014
RO08.10.2014
SE08.10.2014
SK08.10.2014
GR09.01.2015
LU29.01.2015
BE31.01.2015
CH31.01.2015
LI31.01.2015
PT09.02.2015
Former [2015/43]AT08.10.2014
CY08.10.2014
CZ08.10.2014
DK08.10.2014
EE08.10.2014
ES08.10.2014
FI08.10.2014
IT08.10.2014
MC08.10.2014
NL08.10.2014
RO08.10.2014
SE08.10.2014
SK08.10.2014
GR09.01.2015
LU29.01.2015
BE31.01.2015
PT09.02.2015
Former [2015/39]AT08.10.2014
CY08.10.2014
CZ08.10.2014
DK08.10.2014
EE08.10.2014
ES08.10.2014
FI08.10.2014
IT08.10.2014
NL08.10.2014
RO08.10.2014
SE08.10.2014
SK08.10.2014
GR09.01.2015
LU29.01.2015
BE31.01.2015
PT09.02.2015
Former [2015/37]AT08.10.2014
CY08.10.2014
CZ08.10.2014
DK08.10.2014
EE08.10.2014
ES08.10.2014
FI08.10.2014
IT08.10.2014
NL08.10.2014
RO08.10.2014
SE08.10.2014
SK08.10.2014
GR09.01.2015
BE31.01.2015
PT09.02.2015
Former [2015/36]AT08.10.2014
CY08.10.2014
CZ08.10.2014
DK08.10.2014
EE08.10.2014
ES08.10.2014
FI08.10.2014
NL08.10.2014
RO08.10.2014
SE08.10.2014
GR09.01.2015
BE31.01.2015
PT09.02.2015
Former [2015/35]AT08.10.2014
CY08.10.2014
DK08.10.2014
EE08.10.2014
ES08.10.2014
FI08.10.2014
NL08.10.2014
SE08.10.2014
GR09.01.2015
BE31.01.2015
PT09.02.2015
Former [2015/30]AT08.10.2014
CY08.10.2014
ES08.10.2014
FI08.10.2014
NL08.10.2014
SE08.10.2014
GR09.01.2015
BE31.01.2015
PT09.02.2015
Former [2015/26]AT08.10.2014
CY08.10.2014
ES08.10.2014
FI08.10.2014
NL08.10.2014
SE08.10.2014
GR09.01.2015
PT09.02.2015
Former [2015/25]AT08.10.2014
ES08.10.2014
FI08.10.2014
NL08.10.2014
SE08.10.2014
GR09.01.2015
PT09.02.2015
Former [2015/24]ES08.10.2014
FI08.10.2014
NL08.10.2014
SE08.10.2014
GR09.01.2015
PT09.02.2015
Former [2015/23]ES08.10.2014
FI08.10.2014
NL08.10.2014
PT09.02.2015
Former [2015/22]NL08.10.2014
PT09.02.2015
Former [2015/16]NL08.10.2014
Documents cited:Search[A]WO0215894  (TEIJIN LTD [JP], et al) [A] 1-3,13-15 * claim - *;
 [PX]  - NOZOMI SAITO ET AL., "dramatic enhancement of antagonistic activity on vitamin d receptor:a double functionalization of 1 alfa-hydroxyvitamin D3 26,23-lactones.", ORGANIC LETTERS, us, (2003), vol. 5, no. 25, pages 4859 - 4862, XP002474192 [PX] 1-15 * page 4859 - page 4862 *

DOI:   http://dx.doi.org/10.1021/ol035922w
International search[Y]JPH11116551  (TEIJIN LTD);
 [Y]EP1123921  (TEIJIN LTD [JP]);
 [Y]EP0712843  (TEIJIN LTD [JP]);
 [XP]WO03070716  (TEIJIN LTD [JP], et al)
by applicantWO9533716
 WO0024712
 JPH11116551
 WO9850353
 WO0215894
    - BLOOD, (1989), vol. 73, pages 235 - 239
    - BLOOD, (1993), vol. 82, pages 1383 - 1394
    - N. ENGL. J. MED., (1984), vol. 311, pages 1683 - 1685
    - J. CLIN. ENDOCRINOL. METAB., (1985), vol. 60, pages 960 - 966
    - AM. J. MED., (1983), vol. 74, pages 721 - 724
    - N. ENGL. J. MED., (1984), vol. 311, pages 1103 - 1105
    - AM. J. NEPHROL., (1993), vol. 13, pages 275 - 277
    - AM. J. MED. SCI., (1991), vol. 301, pages 178 - 181
    - ANN. INTERN MED., (1986), vol. 105, pages 890 - 891
    - FUJISHIMA ET AL., BIOORG. MED. CHEM., (2000), vol. 8, page 123
    - FUJISHIMA ET AL., BIOORG. MED. CHEM., (2000), vol. 8, no. 123
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.